6533b7dafe1ef96bd126d9b1

RESEARCH PRODUCT

Ventilator-Associated Pneumonia in Patients with COVID-19: A Systematic Review and Meta-Analysis

Marta AlessiMariachiara IppolitoGiulia IngogliaCesare GregorettiGiulia CatalisanoAntonino GiarratanoElisa ConsiglioAndrea CortegianiGiovanni MisseriClaudia Marino

subject

invasive mechanical ventilationMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)RM1-950BiochemistryMicrobiologyArticlelaw.inventionventilator-associated pneumonia03 medical and health sciences0302 clinical medicinePrimary outcomelawInternal medicinemedicinePharmacology (medical)In patient030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsAdult patientsbusiness.industryVentilator-associated pneumoniaCOVID-19030208 emergency & critical care medicinebacterial infections and mycosesmedicine.diseaseIntensive care unitrespiratory tract diseasesmeta-analysisPneumoniaInfectious DiseasesMeta-analysisTherapeutics. Pharmacologybusiness

description

The aim of this systematic review and meta-analysis was to estimate the pooled occurrence of ventilator-associated pneumonia (VAP) among patients admitted to an intensive care unit with COVID-19 and mortality of those who developed VAP. We performed a systematic search on PubMed, EMBASE and Web of Science from inception to 2nd March 2021 for nonrandomized studies specifically addressing VAP in adult patients with COVID-19 and reporting data on at least one primary outcome of interest. Random effect single-arm meta-analysis was performed for the occurrence of VAP and mortality (at the longest follow up) and ICU length of stay. Twenty studies were included in the systematic review and meta-analysis, for a total of 2611 patients with at least one episode of VAP. The pooled estimated occurrence of VAP was of 45.4% (95% C.I. 37.8–53.2%

yearjournalcountryeditionlanguage
2021-05-07Antibiotics
https://doi.org/10.3390/antibiotics10050545